The results declared by the individual companies are derived from the reliable sources likewise Pharmabiz, economic times, india profit etc.
Indoco Remedies net profit dips by 31%, net sales by 10
Indoco Remedies hit by lower domestic sales during the quarter ended June 2009 and its net profit declined sharply by 31.4 per cent to Rs 16.88 crore from Rs 24.60 crore in the similar period of last year. Despite higher exports its net sales declined by 10.2 per cent to Rs 98.34 crore from Rs 109.49 crore. The fall in profit impacted earning per share, which nosedived to Rs 13.74 from Rs 20.02 in the last period.
The company's exports increased by 16.1 per cent, but its domestic formulation sales declined by 17.5 per cent. The sales declined due to it introduction certain credit control measures in the current and previous quarters. However, the de-growth in domestic sales was much lower as compared to earlier quarters. The products like Cyclopam, Tuspel Plus, MCBM-69, Clokit, Febrex Plus Drops, etc., achieved positive trend during the quarter under review.
Exports to regulated market registered a growth of 15 per cent to Rs 22.47 crore from Rs 19.54 crore. Its Baddi facility received UK MHRA approval. The AOK (Germany) tender dispatches are in full swing and its API plant at Patalganga received approval for supply of metformin API for the OAK tender. The exports to emerging markets increased by 24.09 per cent to Rs 4.48 crore from Rs 3.61 crore.
Sanofi-aventis net profit moves up by 29% to €2.3 bn in Q2
Sanofi-aventis, the third largest pharma giant in the World, has clocked impressive performance during the second quarter ended June 2009 on account of better performance by its products like Lantus, Lovenox and Taxotere. Its net profit increased by 29.4 per cent to €2,268 million from €1,753 million in the corresponding period of last year. Its net sales increased by 11.2 per cent to €7,438 million from €6,689 million. The earning per share improved to €1.74 during the quarter from €1.34.
Its consolidated pharmaceutical sales increased to €6,726 million during the second quarter ended June 2009 from €6032 million, representing a growth of 11.5 per cent and consolidated sales of vaccines increased by 8.4 per cent to €712 million from €657 million. The company's sales in Europe improved by 4.6 per cent to €3,079 million. US sales increased by 5.4 per cent to €2,438 million, driven by fine performances from Lantus (up by 28.7 per cent), Taxotere (up by 9.6 per cent) and Eloxatin (up by 10 per cent).
Christopher A Viehbacher, CEO, said, "The group delivered very strong results in the second quarter, driven by solid growth of key pharmaceutical brands and vaccines, strong sales in emerging markets and recent acquisitions. Multaq has just been launched in the US in July. The strong progression of our earnings has led us to raise our guidance for 2009 to EPS growth of around 10 per cent. Since the beginning of the year, we have launched a new R&D approach to increase innovation, we have strengthened our growth platforms through acquisitions, and we are moving forward with the transformation of our company. Those achievements constitute another step toward our vision of becoming a leading diversified global healthcare company with a sustainable growth profile by 2013."
During the first half of 2009, sanofi recorded net sales growth of 6.7 per cent to €14,545 million from €13,626 million in the corresponding period of last year mainly due to appreciation of US Dollar against Euro. Its net profit increased by 22.3 per cent to €4,446 million from €3,636 million. Its R&D expenditure moved up by 3.7 per cent to €2,260 million from €2,180 million.
Dishman Pharma consolidated net surges by 41% in Q1
Dishman Pharmaceutical and Chemicals, a Rs 1062 crore pharma from Ahmedabad, has reported strong growth in profitability during the first quarter ended June 2009 and its consolidated net profit moved up by 41.4 per cent to Rs 39.20 crore from Rs 27.73 crore in the corresponding period of last year. However, its net sales declined by 3.5 per cent to Rs 227.71 crore from Rs 235.87 crore. Its other operating income increased to Rs 15.48 crore from Rs 0.33 crore. With strong growth in profits, its earning per share during the quarter went up to Rs 4.85 from Rs 3.44.
The income from CRAMS activities declined to Rs 168.35 crore from Rs 182.48 crore in the similar period of last year. Its income from marketable molecules went up by 11.2 per cent to Rs 59.36 crore from Rs 53.39 crore.
Orchid Chemicals' net loss at Rs 29.76 cr in Q1
Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) has suffered a setback during the first quarter on account of interest burden, foreign exchange loss and lower operating income. It posted slightly lower net loss for the first quarter ended June 2009 to Rs 29.76 crore as against Rs 31.65 crore in the corresponding period of last year. However, its net sales moved up by 8.2 per cent to Rs 305.82 crore from Rs 282.55 crore.
The profit before interest, depreciation and taxation also moved down by 26.6 per cent to Rs 64.92 crore from Rs 88.33 crore The company provided Rs 29.98 for foreign exchange loss during the quarter under review as against a gain of Rs 3.50 crore. Further its interest burden jumped by 70.8 per cent to Rs 51.66 crore from Rs 30.24 crore. Orchid's other operating income declined to Rs 3.01 crore from Rs 23.77 crore.
The business performance of Orchid during the first quarter of this fiscal remained steady in terms of volumes and revenues. The US generics business gained from an increased demand for Orchid's oral cephalosporin products which has served to counteract the impact of competition in certain injectable products. Orchid's EU generics business has taken off well with the company dispatching key cephalosporin products based on additional approvals secured by the partner, and with Tazobactam-Piperacillin, the key penicillin injection continuing to increase its market share at a steady pace.
During the first quarter of this fiscal, Orchid received its final ANDA approvals for amlodipine besylate tablets and levetiracetam tablets. With this, the cumulative count of Orchid's final ANDA approvals moved to 32, out of which 26 are in the cephalosporin segment and 6 are in the NPNC segment.
Orchid's cumulative ANDA filings in the US market total to 58. The break-up of the total ANDA filings is 29 in the cephalosporins space, 5 in the betalactams space, 21 in NPNC (includes 7 Para IV, First-to-File filings) segment and 3 in the carbapenems segments.
Additional ANDAs which are in the advanced stages of development and analysis will be filed progressively in the ensuing quarters.
The cumulative filing count of applications of Marketing Authorizations in Europe is 29 of which 4 have received approval. The break-up of the total MA filings is 23 in the cephalosporin segment, one in the betalactam segment, two in the carbapenem segment and three in the NPNC segment. In the API (Active Pharmaceutical Ingredients) segment Orchid's cumulative US DMF count is 72. The break-up of the total filings is 26 in the cephalosporin segment, 33 in the NPNC segment, two in the betalactam segment and 11 in the carbapenems segment. In the European market space the cumulative filings of CoS (Certificate of Suitability) count remained at 20 which includes 12 in cephalosporin segment, seven in NPNC segment and one in the betalactam segment. Orchid's Japanese DMF filings remained at three.
